Stericycle, Inc. SRCL is slated to report third-quarter 2018 results on Nov 1, after the bell.
Decline in revenues from the majority of its services is likely to dent the company’s top line in the to-be-reported quarter. The Zacks Consensus Estimate for third-quarter revenues is pegged at $859 million, mirroring a year-over-year decline of 2.7%.
So far this year, shares of Stericycle have lost 27.8% compared with the S&P 500’s 1.8% decline.
Here are the expectations in details.
The Zacks Consensus Estimate for Regulated Waste and Compliance Services third-quarter revenues stands at $474 million, reflecting a year-over-year decline of 5.6%. The expected decline is likely to be due to impacts of divestitures. In the last reported quarter, these revenues declined 5.5%.
The consensus estimate for Communication and Related Services revenues is $77 million, indicating a year-over-year decline of 21%. The anticipated decline is likely to be due to decrease in volumes in Communication Solutions. In second-quarter 2018, these revenues decreased 10.7%.
For Manufacturing and Industrial Services revenues, the consensus mark stands at $80 million, indicating an 8% decline year over year mainly due to divestitures. These revenues were down 2.2% in the first quarter.
The consensus estimate for Secure Information Destruction Services revenues is pegged at $226 million, mirroring 10.2% growth year over year. Higher paper prices driven by increasing demand for recycled paper should support this growth. These revenues increased 8.3% in the second quarter.
Stericycle, Inc. Revenue (TTM)
Stericycle currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Upcoming Releases
Investors interested in the broader Business Services sector are keenly awaiting third-quarter earnings reports from key players like Genpact G, Delphi Technologies DLPH and Green Dot GDOT. While Genpact will report on Nov 6, Delphi Technologies and Green Dot will release quarterly results on Nov 7.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment